Innovent Announces First Patient Dosed in Pivotal Registrational Study of IBI363/TAK-928 (PD-1/IL-2α-biased Bispecific Fusion Protein) in Combination with Bevacizumab in Late-Line Advanced Colorectal Cancer in China

The provided article excerpt contains only a company introduction for Innovent Biologics (HKEX: 01801) and does not include any specific news, financial figures, guidance, regulatory actions, or transactions. As a result, there is no identifiable catalyst or magnitude to assess market impact.

Analysis

The provided article excerpt contains only a company introduction for Innovent Biologics (HKEX: 01801) and does not include any specific news, financial figures, guidance, regulatory actions, or transactions. As a result, there is no identifiable catalyst or magnitude to assess market impact.